Skip to main content

Day: May 15, 2025

Vaso Corporation Announces Financial Results for First Quarter of 2025

PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services, and proprietary medical products, today announced its operating results for the three months ended March 31, 2025. “The Company recorded record first quarter revenue, with revenue of $19.5 million, an increase of 3.9% when compared to the same quarter of the prior year,” commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Gross profit for the quarter was $11.4 million, up by $440 thousand, or 4.0%, year-over-year, and net loss for the first three months of 2025 narrowed to $1.1 million from $1.2 million for the same period of 2024.” “Our balance sheet remains strong, with $25.3 million...

Continue reading

Altai Announces Senior Management Addition

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) — Altai Resources Inc. (TSXV: ATI) (“Altai” or the “Company”) announced today that the Company has added Yana Silina to the senior management team, in the role of Chief Financial Officer (the “CFO”). Ms. Silina is a Chartered Professional Accountant with over 15 years of experience in financial reporting, corporate governance, and regulatory compliance, primarily within the venture capital and resource sectors. Ms. Silina holds a Diploma in Management Studies from Thompson Rivers University and is currently a Senior Accountant at Da Costa Management Corp., where she provides financial consulting and outsourced CFO services to both public and private companies. Ms. Silina also serves as the CFO of StimCell Energetics Inc., Stuhini Exploration Ltd., Tocvan Ventures Corp, and Cascade Copper Corp....

Continue reading

CORRECTION – Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsUpdated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate doses Encouraging preliminary time-to-event data in triple-negative breast cancer (TNBC)Second, higher dose recently selected for expansion in post-topoisomerase-1 inhibitor ADC (post-topo-1) TNBC; patient enrollment advancing...

Continue reading

Kartoon Studios Q1 2025 Revenue Soars 56% Over Prior Year – Company on Track for Profit By End of Year

Mainframe Animation Unit Achieves Profitability, with Revenue up 138% Over Prior Year Quarter and 29% Sequentially Joining Kartoon Channel! and Beacon Media Profitable Units Four Straight Quarters of Growth, Zero Long-Term Debt, Profitable Animation Studio (Mainframe), Profitable Kids Streaming Service (Kartoon Channel!), and Valuable IP Projects Set the Stage for Investor Value Creation BEVERLY HILLS, Calif., May 15, 2025 (GLOBE NEWSWIRE) — Kartoon Studios (NYSE American: TOON) today announced results for the first quarter of 2025, showcasing strong revenue growth, continuing improving margins, and disciplined cost control – all accelerating the Company’s progress toward overall profitability by year-end. Q1 2025 Financial Highlights:Total Revenue up 56.4% year-over-year Production Services Revenue up 137.9% Operating Loss improved...

Continue reading

BranchOut Food Reports Record $3.2M in Q1 Revenue Following Peru Factory Ramp-Up, National Retail Expansion, and $5–6M Ingredient Channel Partnership

Company Reaches Full Vertical Integration with Record Sales; Chinese Tariff Drive Major Retail Opportunity; Strong Momentum Across All Sales Channels Key Highlights:Q1 Revenue of $3.2 Million, up 118% with strong growth anticipated throughout the year Targeted to be debt-free by YE 2025 Peru Facility Fully Operational, supporting $40M+ annual production capacity Expanded Warehouse Club Partnership, now spanning five U.S. regions with multiple products Strategic Ingredient Partnership with MicroDried Signed, with multiple containers shipped in Q1 and projecting $5–6 million in annual ingredient sales. DTC & Brand Strategy Bolstered with the appointment of an experienced Chief Brand Officer to focus on launching the channel. Tariff Tailwinds Favor BranchOut: With tariffs at 30% on imports from China, BranchOut’s Peru-based bulk production...

Continue reading

Nokia and Celesta Capital launch Astranu to advance healthcare imaging technology

Press ReleaseNokia and Celesta Capital launch Astranu to advance healthcare imaging technologyStartup spin-out from Nokia Bell Labs will commercialize advanced healthcare imaging technology. Venture is the first in a Nokia – Celesta collaboration aiming to create a pipeline of spin outs from Nokia Bell Labs technologies. Astranu’s transformative technology delivers a highly performant, cost-effective imaging system for rapid and accurate 3D imaging of middle-ear conditions and hearing response.15 May 2025Murray Hill, New Jersey and San Mateo, California – Nokia and Celesta Capital today announced that Astranu, a company transforming hearing care through next-generation imaging technology, has officially spun out from Nokia as part of a collaboration to accelerate the commercialization of innovative technologies. This marks the inaugural...

Continue reading

C3is Inc. reports financial and operating results for the first quarter of 2025

ATHENS, Greece, May 15, 2025 (GLOBE NEWSWIRE) — C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced today its unaudited financial and operating results for the first quarter ended March 31, 2025. OPERATIONAL AND FINANCIAL HIGHLIGHTSOur handysize dry bulk carriers are on time charters of short-term durations, producing steady cash flows, while our Aframax tanker operates in the spot market, currently achieving voyage charter rates of around $46,000 per day.All of our vessels are unencumbered.Fleet operational utilization of 91.7% for the three months ended March 31, 2025, mainly due to the commercial idle days of the Aframax tanker operating in the spot market. Vessels operating under time charter employment had minimal idle days.Revenues...

Continue reading

Sodexo Inc. announces a new benchmark US dollar notes issue and the launch of a tender offer of certain of its outstanding notes

Sodexo Inc., the US subsidiary of Sodexo S.A., announces today its intention to issue benchmark-sized US dollar-denominated note in one or more tranches, guaranteed by Sodexo S.A. (the “New Notes”), and a concurrent cash tender offer (the “Tender Offer”) for any and all of its existing 1.634% senior notes due 2026 (the “2026 Notes”). The Tender Offer is expected to expire at 5:00 pm, New-York City time, on May 22, 2025 unless extended or earlier terminated. Sodexo Inc. intends to prioritize, at its sole discretion, allocating the New Notes to holders of the 2026 Notes who indicate their firm intention to participate in the Tender Offer and wish to subscribe to the New Notes. The Tender Offer is subject to the successful completion of the issue of the New Notes, at Sodexo Inc.’s discretion. The purpose of the Tender Offer and the proposed...

Continue reading

Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum

30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI DURHAM, NC and LONDON, May 15, 2025 (GLOBE NEWSWIRE) — Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (“MRI”) of the lungs, will be featured at the American Thoracic Society’s (ATS) 2025 Respiratory Innovation Summit (RIS), taking place May 16–17 at the Marriott Marquis in San Francisco, California. Polarean will also attend the ATS 2025 International Conference from May 18–21, continuing its active engagement with leaders across pulmonary medicine. Polarean’s selection as a featured company at RIS 2025 underscores the growing recognition of the company’s Xenon MRI platform as an innovative tool for both...

Continue reading

Cemtrex Reports Second Quarter Fiscal Year 2025 Financial Results

Brooklyn, NY, May 15, 2025 (GLOBE NEWSWIRE) — – Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, has reported its financial and operational results for the fiscal second quarter ended March 31, 2024. Key Highlights for Second Fiscal Quarter 2025Revenue increased 59% to $27.3 million, compared to revenue in the prior year quarter of $17.2 million. Operating Income totaled $4.6 million, compared to an operating loss of $1 million in Q2 FY 2024. Net Income for the period was $8.4 million, compared to a net loss of $1.5 million in Q2 FY 2024. Gross profit margin increased to 45%, up from 40% in the prior year period. Stockholders equity rose to $6.4 million, up from $4.7 million at September 30th 2024.Management Commentary Cemtrex Chairman and CEO, Saagar Govil, commented...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.